Combining artesunate with existing antimalarial drugs may improve cure rates, delay emergence of resistance, and reduce transmission. We performed a randomized comparative trial to quantify the effect of adding artesunate to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in Indonesia. Using a modified 1997 World Health Organization protocol for assessment of therapeutic efficacy of antimalarial drugs, 105 patients (stratified by age/ethnic group) were randomized: 53 received artesunate orally, 4 mg/kg of body weight, a single daily dose for three days, plus sulfadoxine-pyrimethamine orally (1.25 mg of pyrimethamine/kg of body weight), a single dose on day 0, and 52 patients received sulfadoxine-pyrimethamine alone. Six from the combination group were withdrawn from analysis, as were six of the sulfadoxine-pyrimethamine group. Treatment failure rates on day 14 were 0% in the artesunate plus sulfadoxine-pyrimethamine group and 8.7% in the sulfadoxine-pyrimethamine group (P ϭ 0.12). Treatment failure rates on day 28 were 4.4% and 15.2%, respectively (P ϭ 0.16). Relative risk of treatment failure at 28 days was 0.3 (95% confidence interval [CI] ϭ 0.1-1.3). Mean fever clearance time (1.3 versus 1.7 days) and mean parasite clearance time (1.4 versus 2.0 days) were both faster in the artesunate plus sulfadoxinepyrimethamine group than in the sulfadoxine-pyrimethamine group (P ϭ 0.08 and P Ͻ 0.0001, respectively). Only 20 (39.2%) of 51 patients treated with artesunate plus sulfadoxine-pyrimethamine were still parasitemic on day 1 compared with 45 (86.5%) of 52 patients treated with sulfadoxine-pyrimethamine alone (P ϭ 0.000001, relative risk [RR] ϭ 0.4, 95% CI ϭ 0.3-0.6). Gametocyte carriage was lower following artesunate plus sulfadoxine-pyrimethamine than following sulfadoxine-pyrimethamine (RR ϭ 0.5, 95% CI ϭ 0.2-1.0 on day 7 and RR ϭ 0.5, 95% CI ϭ 0.2-1.1 on day 14). Mild diarrhea, rash, and itching resolved without treatment. Combined artesunate plus sulfadoxinepyrimethamine resulted in more rapid fever and parasite clearance, was well tolerated, reduced risk of treatment failure, and lowered gametocyte carriage.
INTRODUCTION
The rationale for combining drugs with independent modes of action and different resistance mechanisms is to improve therapeutic efficacy and to prevent or delay the emergence or development of resistance. 1, 2 This approach has been adopted in cancer chemotherapy, and in the treatment of infection with human immunodeficiency virus, tuberculosis, leprosy, and Pseudomonas infection. In malaria, the combination of artesunate and mefloquine is highly effective against multidrug-resistant Plasmodium falciparum.
In an area of high-level resistance to mefloquine in Thailand, combined treatment of artesunate and mefloquine has not only increased the cure rate to almost 100%, but has also slowed the development of resistance to mefloquine, reduced malaria transmission, and reduced the incidence of P. falciparum malaria. 3Ϫ5 Chloroquine, the current national first-line antimalarial drug, is no longer adequately clinically effective for the treatment of falciparum malaria in eastern Indonesia. Although sulfadoxine-pyrimethamine, the current second-line antimalarial drug, is highly effective in many parts of eastern Indonesia, it is only moderately effective in Irian Jaya with cure rates as low as 73% 6 (Tjitra E and others, unpublished data). If sulfadoxine-pyrimethamine is chosen as a new firstline therapy, it will be prudent to combine this with another antimalarial drug in an attempt to prevent or delay the rapid emergence/development of sulfadoxine-pyrimethamine resistance seen elsewhere in Southeast Asia, South America, and East Africa 7, 8 and already evident in Irian Jaya. In a recent efficacy study in Irian Jaya, combining the existing Indonesian antimalarial drugs chloroquine and sulfadoxinepyrimethamine did not improve the therapeutic efficacy of sulfadoxine-pyrimethamine alone for uncomplicated falciparum malaria (Tjitra E and others, unpublished data). Therefore, use of another therapeutic combination needs consideration to improve cure rates and to slow the development of resistance to sulfadoxine-pyrimethamine.
Combination therapy with sulfadoxine-pyrimethamine plus artesunate may be a good alternative antimalarial regimen in Irian Jaya. The combination of artesunate plus sulfadoxine-pyrimethamine has been shown to rapidly reduce initial parasite biomass protecting sulfadoxine-pyrimethamine against the development of parasite resistance, with sulfadoxine-pyrimethamine eradicating the small residual parasite load at a time of persisting adequate blood concentration. 2 This combination may thus improve cure rates, delay emergence of resistance, and reduce transmission. The need for such trials globally was declared an urgent priority in a recent major multicenter transnational position statement. 9 Only one study of this drug combination has been reported (in Gambian children). 10 The results were promising, and other studies are in progress in Africa. The aim of the current study was to quantify the effect of adding artesunate to sulfadoxine-pyrimethamine treatment in children and adults with uncomplicated falciparum malaria in an area of Indonesia with a higher frequency of sulfadoxine-pyrimethamine treatment failure than the 7.3% found in the Gambian trial site. 
MATERIALS AND METHODS

Study site.
The study was performed at Genyem Health Center, situated in a mesoendemic area of Irian Jaya (Papua), Indonesia from August to November 1999 ( Figure 1 ). Plasmodium falciparum is the predominant species at this site (Tjitra E, unpublished data).
Ethics. Informed consent was obtained from adult participants and from parents or legal guardians of minors. Study design. This was a randomized controlled trial of combined artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in children and adults with uncomplicated symptomatic falciparum malaria. The study was based on the 1997 World Health Organization (WHO) revised in vivo antimalarial drug sensitivity protocol. 11 Patients were observed for 28 days using a standardized drug efficacy record form.
Patients. Patients attending Genyem Health Center were selected according to the 1997 WHO inclusion criteria for assessment of therapeutic efficacy of antimalarial drugs, 11 and were eligible for enrolment if they were six months of age or older and had a thick blood film showing an asexual P. falciparum monoinfection with a parasite density of 1,000-100,000/l, a history of fever during the preceding 48 hr, the ability to return for stipulated follow-up visits, and if an informed consent form was signed by an adult patient or by a parent/guardian for children. Exclusion criteria were severe malnutrition, danger signs of severe and complicated malaria, pregnancy or lactation, a history of hypersensitivity reactions to any other drugs, or febrile diseases other than malaria. 11 Clinical-laboratory examinations. A local nurse obtained a medical history and measured the axillary temperature using a digital electronic thermometer. The study physician then obtained a standardized medical history and performed a physical examination. All patients were re-examined on each day of follow-up in the clinic, including a clinical assessment for adverse reactions.
Blood specimens were collected from finger punctures on days 0, 1, 2, 3, 7, 14, and 28, and on any other day until at least day 14 when the patient became unwell or developed a fever. These were used to prepare thick and thin smears, and blood blots for PCR and genotyping. The hemoglobin level was checked using a battery operated HemoCue portable photometer and direct-reading hemoglobinometer (AB Leo Diagnostics, Helsingborg, Sweden) on days 0, 14, and 28, or on any other day if parasitemia recurred.
Thick and thin films were made in duplicate and stained with 10% Giemsa. All slides were read by an expert microscopist with 20 years experience who was blinded to treatment allocation and clinical status. Parasite density was counted per 200 white blood cells, and was then calculated assuming 8,000 white blood cells/l. A thick smear was considered negative on initial review if no parasites were found in 100 high-power fields. A thin smear was also examined to confirm parasite species. All slides were cross-checked by an experienced microscopist who was also blinded to treatment allocation. Upon cross-checking, at least 200 highpower fields were checked before slides were considered negative. Slides from all parasitologic treatment failures were confirmed as positive by a second experienced microscopist.
Genotyping of acute and convalescent samples was used to distinguish recrudescence of the original parasite strain from reinfection with a new parasite strain. Paired day 0 and convalescent parasite DNA were prepared from blood spotted onto filter paper from those in whom recurrent asexual parasitemia developed following initial clearance. The polymorphic domain of the P. falciparum gene merozoite surface protewin-2 was amplified by a PCR using the primers and conditions as described by Viriyakosol and others. 12 All PCRs were performed in a volume of 50 l using Hot-StarTaq DNA polymerase and the supplied buffer (Qiagen, Victoria, Australia). Digestion with restriction endonucleases and analysis were then performed using the Hinf I restriction enzyme, and results were then confirmed using a second restriction enzyme (Rsa I) as described by Felger and others. 13 Recrudescences were defined as absence of genetic heterogeneity in paired samples. New infections were defined by heterogeneity of paired samples. 13 Treatment. After all eligible patients consented, they were randomized according to a computer-generated sequence of random numbers, and stratified by age (children and adults) and ethnicity (Papuan and non-Papuan). Treatment allocation was concealed by the use of sealed opaque envelopes, which were opened sequentially. In this trial, we randomized patients to either open label artesunate (Artesunate; Mediplantex, Hanoi, Vietnam; 1 tablet ϭ 50 mg; 4 mg/kg of body weight/day, a single oral daily dose for 3 days) plus sulfadoxine-pyrimethamine (Fansidar; F. Hoffmann La Roche, Basel, Switzerland; 1 tablet ϭ 500 mg of sulfadoxine and 25 mg of pyrimethamine; dose based on a pyrimethamine level of 1.25 mg/kg of body weight, a single dose given orally on day 0), or to SP alone. In all cases, administration of the drug was observed by the study team. All patients were kept in the clinic for 1 hr to ensure that they did not vomit. Administration of the study drug was repeated in those who vomited and observation was extended to 2 hr.
If the axillary temperature was Ն 38ЊC, paracetamol was given at a dose of 10 mg/kg of body weight every 8 hr for 24 hr. All treatment failure cases were treated with quinine (10 mg of salt/kg of body weight/dosage, orally 3 times a day for 7 days) plus primaquine (0.50-0.75 mg of base/kg of body weight in a single oral dose in all except infants).
Endpoints. Primary. Therapeutic response on the basis of parasitologic and clinical cure by day 14 and day 28, based on 1997 WHO protocol criteria, 11 was modified to include parasite genotyping to differentiate recrudescence from reinfection. New infections detected by genotyping were classified as non-treatment failures in treatment failure analyses, and were excluded in analyses of cure rates. Tolerability and safety were based on the incidence of adverse reactions. An adverse reaction was defined as the development of any symptom or sign that did not exist before the initiation of treatment that was not a classic symptom or sign of malaria or intercurrent infection.
Secondary. Fever clearance time was defined as the time (days) from initiation of treatment to fever clearance (remaining afebrile by history and with axillary temperature Ͻ 37.5ЊC on the day of follow-up). Parasite clearance time was defined as the time (days) from the initiation of treatment to parasite clearance (parasite count falling below the level of microscopic detection). Hematologic recovery was defined as cured on days 14 and 28, with a hemoglobin level greater than that on day 0. Gametocyte carriage on days 7 and 14 was defined as the proportion of patients with gametocytes on each of these days, 10 stratified by those with and without gametocytes on day 0 and gametocyte density on days 7 and 14.
Additional analyses. Subgroup analysis of therapeutic efficacy was performed using the 1997 WHO protocol criteria. 11 Early treatment failure (ETF) was defined as the development of one of the following during the first three days of follow-up: danger signs or severe malaria on day 1, day 2, or day 3 in the presence of parasitemia; parasitemia on day 2 greater than on day 0; or parasitemia on day 3 Ն 25% of day 0. Late treatment failure (LTF) was defined as the development of one of the following during the follow-up period from day 4 to day 28, without previously meeting any of the criteria of ETF: danger signs or severe malaria after day 3 in the presence of parasitemia with the same species and genotype as on day 0; unscheduled return of the patient because of clinical deterioration in the presence of parasitemia; or the presence of parasitemia on any of the scheduled days of return (days 7, 14, or 28) with the same species and genotype as on day 0. Adequate clinical response (ACR) was defined as the patient not developing any of the criteria of early or late treatment failure, and parasitologic clearance confirmed throughout the follow-up period. Sensitivity of the parasites to antimalarial drugs (S, R1-R3) was determined using the 1967 WHO criteria. 14 Statistical analysis. Sample size calculation was based on a previous adequate clinical response rate 11 to sulfadoxinepyrimethamine of 73% found in 46 patients at the same study site (Tjitra E and others, unpublished data), and an adequate clinical response in all 15 patients treated with combined artesunate plus sulfadoxine-pyrimethamine in a pilot study at the study site six months before the trial started (Tjitra E and others, unpublished data). Fifty-two patients in each group gave 80% power to detect a difference between an anticipated 73% cure rate with sulfadoxine-pyrimethamine and an expected cure rate of 95% with combined ar- tesunate plus sulfadoxine-pyrimethamine (Epi-Info version 6. 04b). 15 All data entry and analysis used Epi-info version 6. 04b. 15 Categorical data for each of primary and secondary endpoints were compared by calculating the chi-square value or by Fisher's exact test. Data on all participants not lost to follow-up were included in an intention-to-treat analysis. Normally distributed continuous data were compared by Student's t-test and analysis of variance. Data not conforming to a normal distribution were compared by the Mann-Whitney U test or the Kruskal-Wallis one-way analysis of variance on ranks. Relative risks of primary and secondary endpoints were obtained by using the sulfadoxine-pyrimethamine group as a reference group, and were presented with 95% confidence intervals.
RESULTS
Patient characteristics.
Of the 105 eligible patients with uncomplicated falciparum malaria, 83.8% were children Յ 12 years old and 16.2% were adults between 13 and 82 years old, with a similar proportion in each treatment group (Table  1) . By chance the median parasitemia was higher in the sulfadoxine-pyrimethamine group and the proportion with gametocytemia was higher in the artesunate plus sulfadoxinepyrimethamine group compared with other groups ( Table 1) . Neither of these differences were statistically different. Other baseline characteristics were similar between each group (Table 1 ). There was one patient with hemoglobin less than 5 g/dl, but without danger signs in the artesunate plus sulfadoxine-pyrimethamine group.
Therapeutic efficacy. During this trial, 12 patients were withdrawn from analysis (based on WHO criteria 11 ), six in each group. Four patients developed mixed infection with P. vivax (all in the sulfadoxine-pyrimethamine group) on days 2-3 requiring alternative antimalarial treatment, seven moved from the study site (five in the artesunate plus sulfadoxine-pyrimethamine group: four on days 1-3 and one on day 14, and two in the sulfadoxine-pyrimethamine group on day 3), and one had a measles infection (artesunate plus sulfadoxine-pyrimethamine group) on day 14 treated with trimethoprim-sulfamethoxazole. Two children vomited, both in the artesunate plus sulfadoxine-pyrimethamine group.
Vomiting did not recur following repeat dosing. Two patients (both in the artesunate plus sulfadoxine-pyrimethamine group) were identified as new infections by genotyping on days 14 and 28.
There was a trend to higher clinical and parasitologic cure (ACR) in the artesunate plus sulfadoxine-pyrimethamine group on both day 14 and day 28 (100% versus 91.3%; P ϭ 0.12 on day 14 and 95.6% versus 84.8%; P ϭ 0.16 on day 28) ( Table 2 ). Overall treatment failure by day 28 was 15.2% (7 of 46) in the sulfadoxine-pyrimethamine group compared with 4.4% (2 of 45) in the artesunate plus sulfadoxine-pyrimethamine group (P ϭ 0.16, relative risk [RR] of treatment failure ϭ 0.29, 95% CI ϭ 0.06-1.33). All treatment failure cases were successfully treated with oral quinine and cured. In an intention to treat analysis, in which participants withdrawn (but not lost to follow-up) and those with new infections detected by genotyping were included for analysis with treatment failures, clinical and parasitologic cure (ACR) remained higher in the artesunate plus sulfadoxine-pyrimethamine group relative to the sulfadoxine-pyrimethamine group both on day 14 There were two ETF patients, all children with TF within three days, one R3 and one R2. Both were in the sulfadoxine-pyrimethamine group (4.3%, 95% CI ϭ 0.5-14.8), with no ETF in the artesunate plus sulfadoxine-pyrimethamine group (P ϭ 0.24) ( Table 2) . Of the 47 patients in the artesunate plus sulfadoxine-pyrimethamine group with complete data, four patients who had previously cleared parasitemia had recurrent parasitemia. Two of these four patients were identified as new infections by genotyping. One (a child) had clinical symptoms on day 14 and a positive immunochromatographic histidine-rich protein-2 (HRP2) antigen test result, 16 and another one (an adult) was positive by microscopy on day 28. The two others (both children), detected on day 21 and day 28 by microscopy, were confirmed by genotyping as LTF with late R1 ( Table 2 ). In the 46 patients in the sulfadoxine-pyrimethamine group who completed the study, there were five (all children) with recurrent parasitemia. All were confirmed by microscopy and genotyping as LTF, one Table 2 ). There were no patients with treatment failure (ETF and LTF) in the artesunate plus sulfadoxine-pyrimethamine by day 14. Mean fever clearance time (1.3 days versus 1.7 days; P ϭ 0.08) and mean parasite clearance time (1.4 days versus 2.0 days; P ϭ 0.000001) were both shorter in the artesunate plus sulfadoxine-pyrimethamine group compared with the sulfadoxine-pyrimethamine group ( Table 3 ). All evaluable patients (50 of 50) treated with combination therapy were afebrile by day 2 compared with only 73.5% (36 of 49) of sulfadoxine-pyrimethamine treated patients (P Ͻ 0.0001) ( Figure 2 ). Parasite clearance was significantly different between the two treatment groups. Only 39.2% (20 of 51) cases were parasitemic by day 1 in the artesunate plus sulfadoxine-pyrimethamine group compared with 86.5% (45 of 52) parasitemic in the sulfadoxine-pyrimethamine group (P ϭ 0.000001) ( Figure 3 ). There was only modest hematologic recovery in both treatment groups by day 14 (artesunate plus sulfadoxine-pyrimethamine 56.5% [26 of 46] versus sulfadoxine-pyrimethamine 45.2% [19 of 42] ; P ϭ 0.29), but there was a trend towards better hematological recovery on day 28 with combination therapy (79.1% [34 of 43] versus 61.5% [24 of 39] ; P ϭ 0.08). Mean changes in hemoglobin between day 14 and day 0 and day 28 and day 0 were not significantly different between groups (Table 3) .
Gametocyte carriage following treatment. A greater proportion of the artesunate plus sulfadoxine group had gametocytes on day 0 (14.9%, 7 of 47) than the sulfadoxinepyrimethamine group (4.3%, 2 of 46). However by days 7 and 14, gametocyte carriage in the artesunate plus sulfadoxine-pyrimethamine group was half that in the sulfadoxinepyrimethamine group (RR ϭ 0.47 [95% CI ϭ 0.21-1.05] and RR ϭ 0.48 [95% CI ϭ 0.21-1.09] on days 7 and 14, respectively) ( Table 3 and Figure 4 ). Among patients still gametocytemic on day 14, mean gametocyte density in those treated with artesunate plus sulfadoxine-pyrimethamine was significantly lower than in those treated with sulfadoxinepyrimethamine group (Table 3 ). In those with an absence of gametocytes on day 0, gametocyte carriage on days 7 and 14 was significantly lower in the artesunate plus sulfadoxinepyrimethamine group than in the sulfadoxine-pyrimethamine alone group (RR ϭ 0.17 [95% CI ϭ 0.04-0.70] on day 7 and RR ϭ 0.18 [95% CI ϭ 0.04-0.77] on day 14, respectively) ( Table 3) .
Adverse reactions. Mild diarrhea (2.1%), rash (4.3%), and itching (2.1%) occurred following artesunate plus sulfadoxine-pyrimethamine treatment, with diarrhea only (2.2%) following sulfadoxine-pyrimethamine treatment (RR of any adverse reaction ϭ 3.91, 95% CI ϭ 0.45-33.72, P ϭ 0.37). These symptoms resolved without treatment.
DISCUSSION
Overall treatment failure was lower with the combination of artesunate plus sulfadoxine-pyrimethamine than with sulfadoxine-pyrimethamine alone. The results of our study in children and adults are comparable with the findings of a recent, large, double-blind, randomized, controlled trial in children in The Gambia (Table 4) . 10 In these studies, the risk of treatment failure with the combination of artesunate plus sulfadoxine-pyrimethamine was approximately 30% that of sulfadoxine-pyrimethamine alone (Irian Jaya, RR ϭ 0.29, 95% CI ϭ 0.06-1.33; Gambia, RR ϭ 0.26, 95% CI ϭ 0.07-0.90) (Table 4) , with a pooled RR, estimated using a fixed effects model, ϭ 0.27 (95% CI ϭ 0.10-0.71). 17 The efficacy of sulfadoxine-pyrimethamine in our study was higher than that expected from previous studies. The difference between treatments in our study did not reach statistical significance, but the study could not be extended because of difficulties in the study site region.
Both early treatment failure cases were in sulfadoxinepyrimethamine-treated non-Papuan children (transmigrants born in Irian Jaya), who usually sleep under bed nets. Parasite rates in these children are usually lower than that in Papuan children. However, the other two non-Papuan children in the sulfadoxine-pyrimethamine group had an adequate clinical response. It is well recognized that host immunity contributes to clearance of parasitemia. 4, 18 Treatment failure rates may be higher in the non-Papuan population in Irian Jaya.
The addition of artesunate to sulfadoxine-pyrimethamine rapidly cleared fever and parasitemia with an adequate clinical response rate of 100% by day 14. Within two days, all patients had become afebrile and aparasitemic. Sulfadoxinepyrimethamine alone proved insufficient to effect a reliable rapid therapeutic response, with fever clearance times and parasite clearance times being significantly slower than for those treated with artesunate plus sulfadoxine-pyrimethamine. Reappearance of parasitemia within three weeks is common when artesunate is used alone, particularly if treatment is given for five days or less. 19 Poor therapeutic responses have been found with both five-day and seven-day treatment courses of artesunate monotherapy for uncomplicated falciparum malaria in multidrug-resistant areas of Indonesia 20 and Thailand. 21 This high recrudescence rate results from the rapid elimination of the drug. 19, 22 The presence of sulfadoxine-pyrimethamine in the blood at effective concentrations during four asexual cycles (Ͼ 6 days) is likely to ensure elimination of residual parasites after the very rapid and substantial reduction of initial parasite biomass with artesunate. 22 In regions of moderately intense malaria transmission such as in Irian Jaya, new infections are not infrequent during the 28-day follow-up period used in this study. With the long half-life of sulfadoxine-pyrimethamine, concentrations may be sufficient to eradicate a sensitive new infection, but insufficient to eradicate a resistant one. 23 Artemisinin derivatives are not only blood schizontocides, but also prevent gametocyte development by their very rapid clearance of asexual stages before commitment to sexual maturation can occur, and by their activity against early stage gametocytes (stage I-III). 24Ϫ26 Resistance of P. falciparum to antimalarials such as chloroquine and pyrimethamine does not affect the susceptibility of its asexual and sexual stages to artemisinin derivatives. 24, 25 A study in Thailand showed gametocyte carriage was significantly lower after artemisinin-derivative combination therapy than after treatment with mefloquine alone. Moreover, re-treatment with artemisinin derivatives reduced subsequent gametocyte carriage compared with re-treatment with either mefloquine or quinine. As a result of reduced gametocyte carriage, the use of artemisinin derivatives with mefloquine in routine treatment in Thailand and Vietnam has been associated with a reduction in both malaria transmission and malaria morbidity. 5, 9 More widespread use of artesunate-containing combination therapy may reduce transmission elsewhere. In Vietnam and Thailand, low endemicity means that most infections are symptomatic, and asymptomatic parasitemia and gametocytemia are rare. However, in high transmission settings such as Irian Jaya, high rates of asymptomatic asexual and sexual parasitemia mean that confining use of artesunate combination therapy to symptomatic infections will likely have at best a modest effect on transmission.
Several million patients have been treated with artesunate in China, Vietnam, and Thailand with no evidence of the adverse neurologic effects described in animals. 9,27Ϫ29 To date only one case of neurotoxicity has been reported after artesunate treatment for falciparum malaria, a patient with ataxia and slurred speech. 30 There is also no evidence for other serious adverse reactions in patients treated with artemisinin derivatives. 28 Severe adverse reactions to sulfadoxine-pyrimethamine such as Stevens-Johnson syndrome occur at a rate of 9-33 per 100,000. 31 In Gambian children, the combination of a three-day course of artesunate given with a single dose of sulfadoxine-pyrimethamine was safe and welltolerated for treatment of uncomplicated falciparum malaria. 32 In our study, adverse reactions were mild, infrequent, and resolved without treatment.
Chloroquine is no longer effective as first-line therapy in Irian Jaya, and an alternative regimen is urgently needed. Switching to sulfadoxine-pyrimethamine alone is not a rational option. Although sulfadoxine-pyrimethamine is only the second-line treatment in Irian Jaya and is not widely available through private vendors, significant rates of sulfadoxine-pyrimethamine treatment failure have already emerged. This suggests that the dihydrofolate reductase (DHFR) codon 108 mutation has already occurred. 10,33Ϫ36 Use of sulfadoxine-pyrimethamine as monotherapy will likely result in the rapid emergence and dissemination of highly sulfadoxine-pyrimethamine resistant parasites (with the DHFR codon 164 mutation) as occurred in Thailand, Vietnam, and South America. 35, 37, 38 Widespread high-grade anti-folate resistance as a result of sulfadoxine-pyrimethamine monotherapy would render both sulfadoxine-pyrimethamine and other antifolates such as chlorproguanil-dapsone ineffective, 39 and would effectively preclude the option of introducing artesunate in combination with either of these cheap antifolate drugs.
Although both our study and the Gambian study demonstrated that artesunate plus sulfadoxine-pyrimethamine is highly efficacious, concern remains that the long half-life of sulfadoxine-pyrimethamine will make this drug combination vulnerable to development of resistance long after the artesunate has cleared. Artesunate plus the shorter half-life chlorproguanil-dapsone may be an alternative, but this is not yet available. To date, there are no efficacy data for chlorproguanil plus dapsone from areas of Southeast Asia outside multi-drug resistant Thailand. 39 Another option is to combine chloroquine with sulfadoxine-pyrimethamine. Until recently, there was a paucity of trial evidence to support this. Recent studies have shown improved efficacy with this combination than with either drug alone. 40, 41 We found no evidence for benefit with the addition of sulfadoxine-pyrimethamine to chloroquine in a small study (Tjitra E and others, unpublished data), although more data from Irian Jaya are required. The very poor adequate clinical response rate with chloroquine in Irian Jaya means that chloroquine may provide little protection against the development of high grade sulfadoxine-pyrimethamine resistance.
The neighboring country of Papua New Guinea also has an unacceptable level of chloroquine treatment failure. In May 2000, the Ministry of Health of Papua New Guinea changed its national antimalarial drug policy, combining sulfadoxine-pyrimethamine with chloroquine/camoquine for first-line therapy for uncomplicated falciparum malaria, with artesunate/artemether plus sulfadoxine-pyrimethamine to be used for treatment failure. 42 The addition of artesunate to sulfadoxine-pyrimethamine as first-line treatment may be the best currently available and affordable option to reduce the high rates of treatment failure now occurring in Irian Jaya, and may delay the further development of anti-folate resistance throughout the province. We have shown that combining sulfadoxine-pyrimethamine with artesunate for the treatment of uncomplicated falciparum malaria resulted in more rapid fever and parasite clearance, was well tolerated, reduced the risk of treatment failure, and lowered gametocyte carriage.
